Ireland: Biosynth Carbosynth expands IVD offering with acquisition of Aalto Bio Reagents

Urs Spitz (left) – CEO and President, Biosynth Carbosynth and Philip Noone (right) – CEO, Aalto Bio Reagents

KKR-backed Biosynth Carbosynth, a materials supplier to the life science industry, has acquired Ireland-based Aalto Bio Reagents is a global provider of proteins, antigens, HIV antibodies and disease state human plasma to the in-vitro diagnostic (IVD) industry. Financial terms were not disclosed. The acquisition broadens Switzerland-based Biosynth’s capabilities and offering to the IVD industry. Aalto’s product…

Membership Required

You must be a HMI Subscriber to view this content.

Subscribe Now »

Already have an account?
Previous articleThe doctor will see you now
Next articleRenaissance Care to spend on energy efficiency and extra capacity
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.